Cargando…
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the num...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528778/ https://www.ncbi.nlm.nih.gov/pubmed/31034926 http://dx.doi.org/10.1016/j.bbcan.2019.04.005 |
_version_ | 1783420302765588480 |
---|---|
author | Nowak-Sliwinska, Patrycja Scapozza, Leonardo Altaba, Ariel Ruiz i |
author_facet | Nowak-Sliwinska, Patrycja Scapozza, Leonardo Altaba, Ariel Ruiz i |
author_sort | Nowak-Sliwinska, Patrycja |
collection | PubMed |
description | The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level. |
format | Online Article Text |
id | pubmed-6528778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-65287782019-05-28 Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer Nowak-Sliwinska, Patrycja Scapozza, Leonardo Altaba, Ariel Ruiz i Biochim Biophys Acta Rev Cancer Review The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level. Elsevier 2019-04 /pmc/articles/PMC6528778/ /pubmed/31034926 http://dx.doi.org/10.1016/j.bbcan.2019.04.005 Text en © 2019 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Nowak-Sliwinska, Patrycja Scapozza, Leonardo Altaba, Ariel Ruiz i Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
title | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
title_full | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
title_fullStr | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
title_full_unstemmed | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
title_short | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
title_sort | drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528778/ https://www.ncbi.nlm.nih.gov/pubmed/31034926 http://dx.doi.org/10.1016/j.bbcan.2019.04.005 |
work_keys_str_mv | AT nowaksliwinskapatrycja drugrepurposinginoncologycompoundspathwaysphenotypesandcomputationalapproachesforcolorectalcancer AT scapozzaleonardo drugrepurposinginoncologycompoundspathwaysphenotypesandcomputationalapproachesforcolorectalcancer AT altabaarielruizi drugrepurposinginoncologycompoundspathwaysphenotypesandcomputationalapproachesforcolorectalcancer |